Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-05
2009-10-06
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S241000
Reexamination Certificate
active
07598283
ABSTRACT:
Compounds having the formulaare useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
REFERENCES:
patent: 5773459 (1998-06-01), Tang et al.
patent: 6177401 (2001-01-01), Ullrich et al.
patent: 6262040 (2001-07-01), Marfat
patent: 6524832 (2003-02-01), Kufe et al.
patent: 7070968 (2006-07-01), Kufe et al.
patent: 2003/0207870 (2003-11-01), Dumas et al.
patent: 2006/0251734 (2006-11-01), Kufe et al.
patent: 2008/0227827 (2008-09-01), Kawabe et al.
patent: 0 136 745 (1984-08-01), None
patent: 816382 (1957-03-01), None
patent: WO 95/21613 (1995-08-01), None
patent: WO 96/23783 (1996-08-01), None
patent: WO 96/40673 (1996-12-01), None
patent: WO 97/37989 (1997-10-01), None
patent: WO 97/42187 (1997-11-01), None
patent: WO 99/00357 (1999-01-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 00/27627 (2000-05-01), None
patent: WO 00/42012 (2000-07-01), None
patent: WO 01/19788 (2001-03-01), None
patent: WO 01/19828 (2001-03-01), None
patent: WO 02/14311 (2002-02-01), None
patent: WO 02/055517 (2002-07-01), None
patent: WO 02/062763 (2002-08-01), None
patent: WO 02/070494 (2002-09-01), None
patent: WO 03/051847 (2003-06-01), None
patent: WO 03/068228 (2003-08-01), None
patent: WO 03/087072 (2003-10-01), None
patent: WO 03/097610 (2003-11-01), None
patent: WO 2004/010995 (2004-02-01), None
patent: WO 2004/022544 (2004-03-01), None
patent: WO 2004/062662 (2004-07-01), None
Cullinan-Bove, et al., “Vascular Endothelial Growth Factor Vascular Permeability Factor Expression in the Rat Uterus: Rapid Stimulation by Estrogen Correlates with Estrogen-Induced Increases in Uterine Capillary Permeability and Growth”, Endocrinology, 133(2), 829-837 (1993).
Derbyshire, et al., “Anti-Tumor and Anti-Angiogenic Effects in Mice of Heparin Conjugated to Angiostatic Steroids”, Int. J. Cancer 63(5), 694-701 (1995).
Mongin, et al., “Regioselectiveortho-Lithiation of Chloro and Bromo Substituted Fluoroarenes”, Tetrahedron Letters 37(36), 6551-6554 (1996).
Passaniti, et al., “Methods in Laboratory Investigation A Simple, Quantitative Method for Assessing Angiogenesis and Antianglogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor”, Laboratory Investigation 67(4) 519-528 (1992).
Rupert, et al., “Suzuki Couplings with Phthalimidines-An Efficient Route to Staurosporinone analogs”, Heterocycles, 45,(11),2217-2221(1997).
Silvagno, et al., “In Vivo Activation ofmetTyrosine Kinase by Heterodimeric Hepatocyte Growth Factor Molecule Promotes Angiogenesis”, Arteriosclerosis, Thrombosis, and Vascular Biology 15(11), 1857-1865 (1995).
Songyang, et al., “Catalytic specificity of proteintyrosine kinases is critical for selective signaling”, Nature 373, 536-539 (1995).
Thistlethwaite, et al., “Human angiopoietin gene expression is a marker for severity of pulmonary hypertension in patients undergoing pulmonary thromboendarterectomy”, J Thorac Cardiovasc Surg, 122(1), 65-73 (2001).
Tyle, “Iontophoretic Devices for Drug Delivery”, Pharmaceutical Research, 3(6), 318-326 (1986).
Voller, et al., “Enzyme-Linked Immunosorbent Assay”, Am. Soc Of Microbiology 2 2ed, 359-371 (1980).
Wilson, et al., “Human Prostate Tumor Angiogenesis in Nude Mice: Metalloprotease and Plasminogen Activator Activities During Tumor Growth and Neovascularization of Subcutaneously Injected Matrigel Impregnated With Human Prostate Tumor Cells”, The Anatomical Record 249, 63-73 (1997).
Dai Yujia
Davidsen Steven K.
Ericsson Anna M.
Hartandi Kresna
Ji Zhiqin
Abbott Laboratories Inc.
James Patricia Coleman
Saeed Kamal A
LandOfFree
Indazole, benzisoxazole, and benzisothiazole kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indazole, benzisoxazole, and benzisothiazole kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazole, benzisoxazole, and benzisothiazole kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4095631